Advertisement

Reactions Weekly

, Volume 1710, Issue 1, pp 160–160 | Cite as

Ibrutinib

Drug resistance: case report
Case report
  • 13 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

An 80-year-old woman developed resistance to ibrutinib during treatment of primary cutaneous diffuse large B-cell lymphoma, leg type [route not stated].

The woman was diagnosed with primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) in May 2012. She received R-CHOP chemoimmunotherapy. After 3 cycles, she achieved a complete metabolic response. She remained in remission until October 2014, when she presented with a lesion on her upper left thigh. A biopsy confirmed relapsed PCDLBCL-LT. She subsequently treated with only radiotherapy. She remained in...

Reference

  1. Fox LC, et al. Molecular mechanisms of disease progression in primary cutaneous diffuse large b-cell lymphoma, leg type during ibrutinib therapy. International Journal of Molecular Sciences 19: 1758, No. 6, 13 Jun 2018. Available from: URL: http://doi.org/10.3390/ijms19061758 - Australia

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations